



LMA International NV

23 August 2006

Announcement to the Singapore Exchange

UPDATE ON PATENT INFRINGEMENT LITIGATION ACTIVITY

**LMA DEUTSCHLAND WINS PATENT
INFRINGEMENT CASE AGAINST AMBU IN GERMANY**

Mainboard-listed LMA International NV (“LMA”), a global leader in the development and marketing of the LMA™ range of supraglottic airway management devices, announced that its wholly-owned subsidiary LMA Deutschland GmbH has been successful in its latest court action to prevent infringement of its intellectual property rights by Ambu Deutschland GmbH (“Ambu”) in Germany.

The Regional Court of Dusseldorf has announced that the Ambu™ laryngeal mask infringes European Patent EP 1 119 386 and has ordered Ambu to cease and desist from offering, selling or using their masks in Germany. Ambu will also be held liable for any damages that have been, or will be, incurred by LMA in Germany as a result of the infringement.

LMA’s patent claim surrounds the inclusion in laryngeal masks of a provision for strengthening the masks at the tip, to aid in insertion. The Court found that all features of the LMA patent are present in the Ambu™ mask. The Court further stated that it has no doubts regarding the validity of LMA’s patent and dismissed Ambu’s request to have the proceedings stayed until a decision is rendered in the parallel pending opposition proceeding before the European Patent Office. The Court has thus indirectly confirmed the validity of LMA’s patent. However, the Court’s decision is not final and Ambu can choose to appeal.

Commenting on the action, Paul Molloy, Chief Operating Officer of LMA, said, “We firmly believe in the merits of our case and are clearly pleased with this decision. LMA invests heavily in research and development to build its extensive portfolio of innovations and will not hesitate to take appropriate action against any infringement of its intellectual property. The Court decision is a victory not only for LMA but for every company committed to innovative product development.”

John Lim, Group President of LMA, added, "Germany is an important market for LMA. As a company that is driven to setting new benchmarks in the supraglottic airway management arena, strong intellectual property protection is one of our business strategies to stay ahead of competition."

LMA International NV

PO Box 862, Osprey House, Old Street, Jersey, Channel Islands JE4 2ZZ

ENDS

FOR FURTHER INFORMATION, PLEASE CONTACT:

Maria Gianoutsos, IP Consultant, LMA International NV, +44 (0)1923 841756

Sharon Seetho, Gavin Anderson & Company, Singapore, +65 9009 8495

NOTES:

LMA International NV

Incorporated in the Netherlands Antilles in 1998, LMA was listed on the Singapore Exchange in March 2005. LMA designs, develops, markets and distributes medical equipment, principally the LMA™ range of supraglottic airway management devices. These devices are used by physicians to allow respiration, provide ventilation to, and support the airway of patients undergoing surgical procedures and life-saving interventions. Since its first product, the LMA-Classic™, was approved by the FDA for use in the United States in 1991, LMA's growth has been driven by the development of innovative products, geographic expansion, and increased customer awareness of the LMA™ airway as an alternative airway management device. LMA has established a leading position in this growing market.

LMA has an office in Jersey, Channel Islands, and subsidiaries in Singapore, Germany and San Diego, California. Through its 50 percent joint venture in LMA Urology Limited, the Group has a subsidiary in Switzerland to design, manufacture and distribute the LMA StoneBreaker™. DBS Bank and Credit Suisse were the Joint Global Coordinators and Joint Bookrunners for the Initial Public Offering of shares in LMA.

LMA™ Airways

For over 20 years, The Laryngeal Mask Company Limited has been making advances in airway design and technology which have impacted directly on patient safety and comfort. British anaesthetist Dr Archie Brain designed the first LMA™ airway in 1988. Since then, LMA™ airways have been used over 200 million times around the world and are supported by over 2,500 published references. The LMA™ airway has become the most well-known and respected supraglottic airway device worldwide, with a full range of products designed for specialist clinical needs including routine anaesthesia, PPV, ENT surgery, the difficult airway and emergency situations.

LMA Patent Portfolio

LMA has an extensive patent portfolio that protects the key products in the LMA™ range, as well as new products currently under development. The Company's portfolio comprises an estimated 315 granted and pending patents worldwide, the majority of which have a significant unexpired term. Of the Company's granted patents, the earliest expiry date is 2008, and the latest is around 2025.